Skopos Labs, Inc. Regenxbio Inc. Transaction History
Skopos Labs, Inc.
- $453 Million
- Q1 2025
A detailed history of Skopos Labs, Inc. transactions in Regenxbio Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 5,583 shares of RGNX stock, worth $57,784. This represents 0.01% of its overall portfolio holdings.
Number of Shares
5,583
Previous 2,117
163.72%
Holding current value
$57,784
Previous $16,000
143.75%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding RGNX
# of Institutions
182Shares Held
45.4MCall Options Held
64.9KPut Options Held
103K-
Black Rock Inc. New York, NY8.61MShares$89.1 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.79MShares$49.6 Million3.6% of portfolio
-
Jpmorgan Chase & CO New York, NY4.36MShares$45.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$35.9 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.07MShares$21.4 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $447M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...